Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Larsen, Sanne Bøjet ^a   Grove, Erik Lerkevang ^a   Neergaard Petersen, Søs ^a   Würtz, Morten ^a   Hvas, Anne Mette ^a,b   Kristensen, Steen Dalby ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CITRIC ACID; COLLAGEN; HIRUDIN; THROMBOXANE B2; ANTITHROMBOCYTIC AGENT;

AGED; ANAMNESIS; ANTICOAGULATION; ARTICLE; BODY MASS; COHORT ANALYSIS; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG RESPONSE; ENTERIC COATED TABLET; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; SEX DIFFERENCE; SMOKING; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MIDDLE AGED; MYOCARDIAL INFARCTION;

AGED; ASPIRIN; BODY MASS INDEX; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; THROMBOXANE B2;

EID: 84930672019     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126767     Document Type: Article

References (44)

1. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009 May 30; 373(9678):1849-60. doi: 10.1016/S0140-6736(09)60503-1 PMID: 19482214
2. Rocca B, Dragani A, Pagliaccia F. Identifying determinants of variability to tailor aspirin therapy. Expert Rev Cardiovasc Ther 2013 Mar; 11(3):365-79. doi: 10.1586/erc.12.144 PMID: 23469916
3. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007 Aug 13; 167(15):1593-9. PMID: 17698681
4. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008 Jan 26; 336(7637):195-8. doi: 10.1136/ bmj.39430.529549.BE PMID: 18202034
5. Kuzniatsova N, Shantsila E, Blann A, Lip GY. A contemporary viewpoint on 'aspirin resistance'. Ann Med 2012 Mar 1; 44(8):773-83. doi: 10.3109/07853890.2011.605388 PMID: 22380694
6. Wurtz M, Grove EL. Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance. Curr Pharm Des 2012; 18(33):5344-61. PMID: 22724409
7. Grinstein J, Cannon CP. Aspirin Resistance: Current Status and Role of Tailored Therapy. Clin Cardiol 2012 Jun 27; 35(11):673-81. doi: 10.1002/clc.22031 PMID: 22740110
8. Larsen SB, Neergaard-Petersen S, Grove EL, Kristensen SD, Hvas AM. Increased platelet aggregation and serum thromboxane levels inaspirin-treatedpatients with prior myocardial infarction. Thromb Haemost 2012 Apr 26; 108(1):140-7. doi: 10.1160/TH12-01-0026 PMID: 22534977
9. Larsen SB, Grove EL, Kristensen SD, Hvas AM. Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease. Thromb Haemost 2013 May 2; 109(5):920-9. doi: 10.1160/TH12-09-0666 PMID: 23407706
10. Wurtz M, Grove EL, Wulff LN, Kaltoft AK, Tilsted HH, Jensen LO, et al. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. JACC Cardiovasc Interv 2010 Aug; 3(8):828-35. doi: 10.1016/j.jcin.2010.05.014 PMID: 20723855
11. Wurtz M, Wulff LN, Grove EL, Kristensen SD, Hvas AM. Influence of renal function and platelet turnover on the antiplatelet effect of aspirin. Thromb Res 2012 Apr 1; 129(4):434-40. doi: 10.1016/j.thromres. 2011.07.019 PMID: 21839494
12. Schmidt M, Maeng M, Jakobsen CJ, Madsen M, Thuesen L, Nielsen PH, et al. Existing data sources for clinical epidemiology: The Western Denmark Heart Registry. Clin Epidemiol 2010; 2:137-44. PMID: 20865111
13. Grove EL, Hvas AM, Johnsen HL, Hedegaard SS, Pedersen SB, Mortensen J, et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010 Jun; 103(6):1245-53. doi: 10.1160/ TH09-08-0527 PMID: 20352155
14. Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009 Feb; 30(4):426-35. doi: 10.1093/eurheartj/ehn562 PMID: 19174428
15. Patrono C, Rocca B. Drug insight: aspirin resistance-fact or fashion? Nat Clin Pract Cardiovasc Med 2007 Jan; 4(1):42-50. PMID: 17180149
16. Wurtz M, Hvas AM, Kristensen SD, Grove EL. Platelet aggregation is dependent on platelet count in patients with coronary artery disease. Thromb Res 2012 Jan 1; 129(1):56-61. doi: 10.1016/j.thromres. 2011.08.019 PMID: 21917303
17. Lordkipanidze M, Diodati JG, Turgeon J, Schampaert E, Palisaitis DA, Pharand C. Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin. Int J Cardiol 2010 Aug 6; 143(1):43-50. doi: 10.1016/j.ijcard.2009.01.037 PMID: 19215991
18. Narvaez I, Sagastagoitia JD, Vacas M, Saez Y, Lafita M, Monica S, et al. Prevalence and biologic profile of aspirin resistance in patients with angiographically proven coronary artery disease. Thromb Res 2007; 120(5):671-7. PMID: 17331566
19. Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005 Oct 4; 46 (7):1258-63. PMID: 16198840
20. Furman MI, Benoit SE, Barnard MR, Valeri CR, Borbone ML, Becker RC, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998 Feb; 31(2):352-8. PMID: 9462579
21. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49(2):71-87. doi: 10.2165/11318100-000000000-00000 PMID: 20067334
22. Cesari F, Marcucci R, Caporale R, Paniccia R, Romano E, Gensini GF, et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2008 May; 99(5):930-5. doi: 10.1160/TH08-01-0002 PMID: 18449424
23. Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011 Jan; 9 (1):185-91. doi: 10.1111/j.1538-7836.2010.04115.x PMID: 20955349
24. Hamsten A, Svensson J, Walldius G, Szamosi A, de FU. Shortened megakaryocyte-platelet regeneration time in young survivors of myocardial infarction. Am Heart J 1985 Dec; 110(6):1154-60. PMID: 2866703
25. Grove EL, Gregersen S. Antiplatelet therapy in patients with diabetes mellitus. Curr Vasc Pharmacol 2012 Jul; 10(4):494-505. PMID: 22272895
26. Ferreiro JL, Angiolillo DJ. Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease. Curr Pharm Des 2012; 18(33):5273-93. PMID: 22724415
27. Mortensen SB, Larsen SB, Grove EL, Kristensen SD, Hvas AM. Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thromb Res 2010 Oct; 126(4): e318-e322. doi: 10.1016/j.thromres.2010.03.013 PMID: 20451957
28. Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res 2004; 113(2):101-13. PMID: 15115665
29. Bordeaux BC, Qayyum R, Yanek LR, Vaidya D, Becker LC, Faraday N, et al. Effect of obesity on platelet reactivity and response to low-dose aspirin. Prev Cardiol 2010; 13(2):56-62. doi: 10.1111/j.1751- 7141.2009.00058.x PMID: 20377806
30. Peace A, McCall M, Tedesco T, Kenny D, Conroy RM, Foley D, et al. The role of weight and enteric coating on aspirin response in cardiovascular patients. J Thromb Haemost 2010 Oct; 8(10):2323-5. doi: 10.1111/j.1538-7836.2010.03997.x PMID: 20653839
31. Bonello-Palot N, Armero S, Paganelli F, Mancini J, de LA, Bonello C, et al. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009 Dec 1; 104(11):1511-5. doi: 10.1016/j.amjcard.2009.07.015 PMID: 19932784
32. Mayer K, Orban M, Bernlochner I, Braun S, Schulz S, Gross L, et al. Predictors of antiplatelet response to prasugrel during maintenance treatment. Platelets 2014 Jan 16;In Press.
33. Rocca B, Petrucci G. Variability in the responsiveness to low-dose aspirin: pharmacological and disease-related mechanisms. Thrombosis 2012; 2012:376721. doi: 10.1155/2012/376721 PMID: 22288010
34. Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999 Feb; 48(2):426-9. PMID: 10334326
35. Vaturi M, Vaduganathan M, Bental T, Solodky A, Kornowski R, Lev EI. Relation of aspirin response to age in patients with stable coronary artery disease. Am J Cardiol 2013 Jul 15; 112(2):212-6. doi: 10. 1016/j.amjcard.2013.03.022 PMID: 23566542
36. Silvain J, Cayla G, Hulot JS, Finzi J, Kerneis M, O'Connor SA, et al. High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. Eur Heart J 2011 Nov 7; 33 (10):1241-9. doi: 10.1093/eurheartj/ehr407 PMID: 22067090
37. Qayyum R, Becker DM, Yanek LR, Moy TF, Becker LC, Faraday N, et al. Platelet inhibition by aspirin 81 and 325 mg/day in men versus women without clinically apparent cardiovascular disease. Am J Cardiol 2008 May 1; 101(9):1359-63. doi: 10.1016/j.amjcard.2007.12.038 PMID: 18435972
38. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 2006 Mar 22; 295(12):1420-7. PMID: 16551714
39. Ikonomidis I, Lekakis J, Vamvakou G, Andreotti F, Nihoyannopoulos P. Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. Am Heart J 2005 May; 149(5):832-9. PMID: 15894964
40. Mirkhel A, Peyster E, Sundeen J, Greene L, Michelson AD, Hasan A, et al. Frequency of aspirin resistance in a community hospital. Am J Cardiol 2006 Sep 1; 98(5):577-9. PMID: 16923439
41. Breddin HK. Can platelet aggregometry be standardized? Platelets 2005 May; 16(3-4):151-8.
42. Zhang HZ, Yu LH, Kim MH. Effect of different anticoagulants on multiple electrode platelet aggregometry after clopidogrel and aspirin administration in patients undergoing coronary stent implantation: a comparison between citrate and hirudin. Platelets 2013; 24(5):339-47. doi: 10.3109/09537104.2012.698431 PMID: 22774770
43. Kaiser AF, Neubauer H, Franken CC, Kruger JC, Mugge A, Meves SH. Which is the best anticoagulant for whole blood aggregometry platelet function testing? Comparison of six anticoagulants and diverse storage conditions. Platelets 2012; 23(5):359-67. doi: 10.3109/09537104.2011.624211 PMID: 21999185
44. Lindhout T, Blezer R, Hemker HC. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb Haemost 1990 Nov 30; 64(3):464-8. PMID: 2096492